Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
← catalyst calendarNCT07536269 · readout ≤ 590 d
Sponsored by Neurocrine Biosciences (industry) · NBIX — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Apr 2026 | estimated | When the study began enrolling |
| Primary completion | Mar 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Congenital Adrenal Hyperplasia
Intervention
- Drug: Crinecerfont
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-emergent Adverse Events (TEAE)
measured Day 1 up to 28 weeks
Permalink · NBIX's whole pipeline · Catalyst calendar · Every registered study · What changed